AR130828A1 - Método para tratar el cáncer - Google Patents
Método para tratar el cáncerInfo
- Publication number
- AR130828A1 AR130828A1 ARP230102814A ARP230102814A AR130828A1 AR 130828 A1 AR130828 A1 AR 130828A1 AR P230102814 A ARP230102814 A AR P230102814A AR P230102814 A ARP230102814 A AR P230102814A AR 130828 A1 AR130828 A1 AR 130828A1
- Authority
- AR
- Argentina
- Prior art keywords
- treating cancer
- compound
- pharmaceutically acceptable
- acceptable salt
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto de fórmula (1). Un compuesto con la fórmula (1), o una sal farmacéuticamente aceptable de este, seleccionado de los compuestos descritos en la Lista 1, o una sal farmacéuticamente aceptable de cualquiera de los anteriores. Una composición farmacéutica que comprende un compuesto de cualquiera de las reivindicaciones 1 - 160 y una sal farmacéuticamente aceptable de esta.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263418102P | 2022-10-21 | 2022-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130828A1 true AR130828A1 (es) | 2025-01-22 |
Family
ID=89068752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102814A AR130828A1 (es) | 2022-10-21 | 2023-10-20 | Método para tratar el cáncer |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR130828A1 (es) |
| TW (1) | TW202421629A (es) |
| WO (1) | WO2024086804A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202303419D0 (en) * | 2023-03-08 | 2023-04-19 | Otsuka Pharma Co Ltd | Compounds |
| WO2025085703A1 (en) * | 2023-10-20 | 2025-04-24 | Scorpion Therapeutics, Inc. | Methods for treating p53-associated cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220257569A1 (en) * | 2018-09-12 | 2022-08-18 | The Governing Council Of The University Of Toronto | Indole-oxadiazole compounds and their therapeutic use |
| US11807644B2 (en) * | 2020-05-12 | 2023-11-07 | Pmv Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
| WO2021262484A1 (en) * | 2020-06-24 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
-
2023
- 2023-10-20 AR ARP230102814A patent/AR130828A1/es unknown
- 2023-10-20 WO PCT/US2023/077433 patent/WO2024086804A1/en not_active Ceased
- 2023-10-20 TW TW112140298A patent/TW202421629A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202421629A (zh) | 2024-06-01 |
| WO2024086804A1 (en) | 2024-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR130828A1 (es) | Método para tratar el cáncer | |
| AR126251A1 (es) | Inhibidores de cdk2 | |
| AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
| AR133968A1 (es) | Nuevo compuesto derivado de ftalazina como inhibidor de sos1 y uso del mismo | |
| MX2020011868A (es) | Inhibidores de los receptores erbb. | |
| MX2024010399A (es) | Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias | |
| CO2024001367A2 (es) | Compuestos antivirales | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| AR132007A1 (es) | Compuestos y métodos para modular ras-pi3k | |
| AR133988A1 (es) | Inhibidores de ras-pi3k y usos de los mismos | |
| CO2024006727A2 (es) | Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos | |
| CL2021003139A1 (es) | Compuestos tricíclicos | |
| DOP2025000009A (es) | Inhibidores de acc novedosos | |
| MX2024013311A (es) | Degradadores bcl-xl heterobifuncionales de tetrahidroisoquinolina | |
| CL2024002379A1 (es) | Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso | |
| CO2025016753A2 (es) | Inhibidores de gsk3α y métodos de uso de estos | |
| MX2020011367A (es) | Compuesto oxo-sustituido. | |
| AR118141A1 (es) | Compuestos para el tratamiento, alivio o prevención de trastornos asociados con los agregados de tau | |
| MX2025005392A (es) | Composicion farmaceutica que comprende un inhibidor de aak1 | |
| AR132764A1 (es) | Inhibidores de tyk2 y sus usos | |
| AR132818A1 (es) | Compuestos para la degradación de la cinasa egfr | |
| AR131842A1 (es) | Métodos para tratar gliomas | |
| NI200700323A (es) | 4-anilino-3-quinolinocarbonitrilo para el tratamiento de cáncer | |
| AR131708A1 (es) | Protacts degradantes de kras a base de cereblon y usos relacionados con los mismos | |
| AR122689A1 (es) | Degradadores de braf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |